Strs Ohio Increases Position in Insulet Corporation $PODD

Strs Ohio boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 36.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,680 shares of the medical instruments supplier’s stock after acquiring an additional 6,003 shares during the period. Strs Ohio’s holdings in Insulet were worth $6,447,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PODD. Worldquant Millennium Advisors LLC purchased a new stake in Insulet during the 2nd quarter valued at about $80,082,000. Squarepoint Ops LLC grew its stake in Insulet by 11,905.8% during the 3rd quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after acquiring an additional 225,377 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in Insulet by 37.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after acquiring an additional 156,009 shares in the last quarter. Parnassus Investments LLC purchased a new stake in Insulet during the 3rd quarter valued at about $46,525,000. Finally, Nordea Investment Management AB grew its stake in Insulet by 35.0% during the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after acquiring an additional 142,922 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $171.39 on Tuesday. The firm’s 50 day moving average price is $216.37 and its 200-day moving average price is $267.14. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. Insulet Corporation has a one year low of $158.35 and a one year high of $354.88. The firm has a market cap of $11.87 billion, a P/E ratio of 48.97, a P/E/G ratio of 1.03 and a beta of 1.20.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same period in the prior year, the business posted $1.15 EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, equities research analysts predict that Insulet Corporation will post 6.27 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PODD shares. Raymond James Financial dropped their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Oppenheimer decreased their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. The Goldman Sachs Group decreased their target price on shares of Insulet from $326.00 to $277.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Leerink Partners decreased their target price on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Finally, Stifel Nicolaus decreased their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Eighteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $327.24.

Insider Activity at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.